

Merchant & Gould

An Intellectual Property Law Firm

RECEIVED
CENTRAL FAX CENTER

MAR 21 2005

3200 IDS Center
80 South Eighth Street
Minneapolis, Minnesota
55402-2215 USA
TEL 612.332.5300
FAX 612.332.9081
www.merchant-
gould.com

A Professional Corporation

Fax Transmission | March 21, 2005TO: Commissioner for Patents
Attn: Examiner Gary B. Nickol
P.O. Box 1450
Alexandria, VA 22313-1450

FROM: Katherine M. Kowalchyk

OUR REF: 11669.192USC1
TELEPHONE: 612.371.5311Total pages, including cover letter: 6PTO FAX NUMBER 1-703.872.9306

If you do NOT receive all of the pages, please telephone us at 612.371.5204, or fax us at 612.332.9081.


Title of Document Transmitted:

INFORMATION DISCLOSURE
STATEMENT AND FORM 1449Applicant: GERRITSEN ET AL.
Serial No.: 10/811.080
Filed: MARCH 26, 2004
Group Art Unit: 1642
Our Ref. No.: 11669.192USC1
Confirmation No. 8064

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: Katherine M. Kowalchyk
Name: Katherine M. Kowalchyk
Reg. No.: 36,848

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Sheryl A. Boerboom
SignatureMarch 21, 2005
Date

GEN033.DOT

S/N 10/811,080

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GERRITSEN ET AL. Examiner: G. NICKOL
Serial No.: 10/811,080 Group Art Unit: 1614
Filed: MARCH 26, 2004 Docket No.: 11669.192USC1
Confirmation No.: 8064 Customer No.: 23552
Title: NOVEL POLYPEPTIDES, THEIR NUCLEIC ACIDS, AND
METHODS FOR THEIR USE IN ANGIOGENESIS AND
VASCULARIZATION


RECEIVED
CENTRAL FAX CENTER

MAR 21 2005

CERTIFICATE UNDER 37 CFR 1.8(b):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on March 21, 2005.

By:



Name: Sheryl A. Boelboom

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(d), a copy of each document or other information listed on the enclosed Form 1449 is not provided because it was previously cited by or submitted to the U.S. Patent and Trademark Office in parent application, U.S. Serial No. 09/684,458 filed on October 5, 2000.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.



Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: March 21, 2005


Katherine M. Kowalchyk
Reg. No. 36,848



03-21-05

12:24

FROM-Merchant & Gould

RECEIVED
CENTRAL FAX CENTER

6123329081

T-811 P.004/006 F-236

MAR 21 2005

Date Mailed: March 21, 2005

Sheet 1 of 3

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.192USCI	Application Number: 10/811,080
	Applicant: GERRITSEN ET AL.	
	Filing Date: 03/26/2004	Group Art Unit: 1614

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,650,282	07/22/1997	Keating et al.			
	5,871,697	02/16/1999	Rothberg et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	WO 99/06423	02/11/1999	PCT			
	WO 00/73469	07/12/2000	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
		Alberts et al., <i>Molecular Biology of the Cell</i> , 3rd Edition, p. 465 (1994)				
		Alberts et al., <i>Molecular Biology of the Cell</i> , 4th Edition anonymous, New York: Garland Science, p. 435 (2002)				
		Berger et al., "Predicting coiled coils by use of pairwise residue correlations", <i>Proc. Natl. Acad. Sci. USA</i> , 92:8259-8263 (1995)				
		Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions", <i>Science</i> , 1306-1310 (1990)				
		Burkhard et al., "Coiled coils: a highly versatile protein folding motif", <i>Trends Cell Biol.</i> , 11:82-88 (2001)				
		DATABASE EMBL SEQUENCES (Online), Accession No. A1684747, May 23, 1999 (2 pages)				
		DATABASE EMBL SEQUENCES (Online), Accession No. Q9NXBB, October 1, 2000 (1 page)				
		Davis et al., "An alpha 2 beta 1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix", <i>Exp Cell Res</i> , 224:39-51 (1996)				
		Dentelli et al., "Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation", <i>J. Immunol.</i> , 163:2151-2159 (1999)				
		Dragoni et al., "EDF-1, a Novel Gene Product Down-regulated in Human Endothelial Cell Differentiation", <i>J. Bio. Chem.</i> , 273(47):31119-31124 (1998)				
		Ellson et al., "The PX domain: a new phosphoinositide-binding module", <i>J. Cell Sci.</i> , 115:1099-1105 (2002)				
		Folkman et al., "Induction of angiogenesis during the transition from hyperplasia to neoplasia", <i>Nature</i> , 339(6219):58-61 (1989)				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: March 21, 2005

Sheet 1 of 3

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.192USC1	Application Number: 10/811,080
	Applicant: GERRITSEN ET AL.	
	Filing Date: 03/26/2004	Group Art Unit: 1614

	Fu et al., <i>EMBO Journal</i> , 15:4392-4401 (1996)
	Gattiker et al., "ScanProsite: A reference implementation of a PROSITE scanning tool", <i>Applied Bioinformatics</i> , 1:107-108 (2002)
	GenBank NP_060241, <i>PX serine/threonine kinase (Homo sapiens)</i>
	Horton et al., "Better prediction of protein cellular localization sites with the k nearest neighbors classifier", <i>Proc. Int. Conf. Intell. Syst. Mol. Biol.</i> , 5:147-152 (1997)
	Hua et al., "Support vector machine approach for protein subcellular localization prediction", <i>Bioinformatics</i> , 17:721-728 (2001)
	Ilan et al., "Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis", <i>J. Cell Sci.</i> , 111(Pt 24):3621-3631 (1998)
	Juarez et al., "Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain", <i>Cancer Res.</i> , 62:5344-5350 (2002)
	Lupas, "Coiled coils: new structures and new functions", <i>Trends Biochem. Sci.</i> , 21:375-382 (1996)
	Lupas, "Prediction and analysis of coiled-coil structures", <i>Methods Enzymol.</i> , 216:513-525 (1996)
	Lupas et al., "Predicting coiled coils from protein sequences", <i>Science</i> , 252:1163-1164 (1991)
	Meggio et al., "One-thousand-and-one substrates of protein kinase CK2?", <i>FASEB J.</i> , 17:349-368 (2003)
	Mendell et al., "When the message goes awry: disease-producing mutations that influence mRNA content and performance", <i>Cell</i> , 107:411-414 (2001)
	Nielsen et al., "Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites", <i>Protein Eng.</i> , 10:1-6 (1997)
	Nielsen et al., "A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites", <i>Int. J. Neural Syst.</i> , 8:581-599 (1997)
	Parry, "Coiled-coils in alpha-helix-containing proteins: analysis of the residue types within the heptad repeat and use of these data in the prediction of coiled-coils in other proteins", <i>Biosci. Rep.</i> , 2:1017-1024 (1982)
	Sassone-Corsi, "Transcription factors responsive to cAMP", <i>Annu. Rev. Cell Dev. Biol.</i> , 11:355-377 (1995)
	Sato et al., "Location, location, location: membrane targeting directed by PX domains", <i>Science</i> , 294:1881-1885 (2001)
	Shinkets et al., "Gene expression analysis by transcript profiling coupled to a gene database query", <i>Nature Biotechnology</i> , 17(8):798-803 (1999)
	Soeda et al., "An attempt to promote neo-vascularization by employing a newly synthesized inhibitor of protein tyrosine phosphatase", <i>FEBS Letters</i> , 524:54-58 (2002)
	St. C. Buchanan et al., "Structural and functional diversity in the leucine-rich repeat family of proteins", <i>Prog. Biophys. Molec. Biol.</i> , 65:1-44 (1996)
	Weidner et al., "Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma", <i>New England J. of Medicine</i> , 324(1):1-8 (1991)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: March 21, 2005

Sheet 3 of 3

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.192USCI	Application Number: 10/811,080
	Applicant: GERRITSEN ET AL.	
	Filing Date: 03/26/2004	Group Art Unit: 1614

		Xin et al., "Peroxisome proliferators-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo", <i>J. Biol. Chem.</i> , 274:9116-9121 (1999)
		Xu et al., "The Phox homology (PX) domain, a new player in phosphoinositide signaling", <i>Biochem. J.</i> , 360:513-530 (2001)

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U S. DEPARTMENT OF COMMERCE